Comment on long-acting lanreotide inducing clinical and biochemical remission of acromegaly caused by disseminated GHRH secreting carcinoid [4]

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 5, 1999, Pages 1761-1762

  Krassowski, Janusz ^a   Zgliczyński, Wojciech ^a   Jeske, Wojciech ^a   Zgliczyński, Stefan ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; LONG ACTING DRUG; SOMATOMEDIN C;

ACROMEGALY; ADULT; APUDOMA; BRONCHUS CARCINOID; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; ECTOPIC HORMONE PRODUCTION; HUMAN; LETTER; LIVER METASTASIS; MALE; PRIORITY JOURNAL; REMISSION; THYROID TUMOR; THYROIDECTOMY; TREATMENT OUTCOME;

ACROMEGALY; ADULT; ANTINEOPLASTIC AGENTS; CARCINOID TUMOR; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MALE; PEPTIDES, CYCLIC; SOMATOSTATIN; THYROID NEOPLASMS;

BRONCHUS;

EID: 0033342438     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone- releasing hormone-secreting carcinoid
2. Acromegaly caused by the ectopic GHRH secretion by the bronchial carcinoid
3. The somatostatin analog (SR-Lanreotide) pretreatment improves the surgical outcome in acromegalic patients harbouring pituitary tumors with somatostatin receptors